OR WAIT null SECS
Jehangir Hospital, along with its research arm Jehangir Clinical Development Centre (JCDC), is bringing its patients access to international clinical trials by joining Clinerion’s Patient Network Explorer platform. JCDC is the research arm of Jehangir Hospital, Pune, India. The hospital has over 350 beds, servicing patients throughout Pune and beyond. It has a wide range of disease-area specializations, including, but not limited to: cardiology, oncology, endocrinology, pediatrics, rheumatology, dermatology and infectious diseases. JCDC has over 60 principal investigators and conducts on average 25-30 clinical studies at any point of time.
Clinerion’s Patient Network Explorer helps partner hospitals be visible to pharmaceutical companies seeking suitable patients and sites for their clinical trials. Queries based on trial protocols may be sent to partners to assess the count of eligible patients in their electronic health records. All patient data is de-identified and remains under the control of the hospital and inside its IT infrastructure. However, Clinerion’s patented technology also enables authorized trial staff at the hospital to re-identify the patient for the purpose of trial recruitment.
“We at JCDC are delighted about partnering with Clinerion as there is an ideal alignment of Clinerion’s innovative technology and our clinical research expertise,” says Pathik Divate, CEO of the JCDC. “We are excited about harnessing the power of this technology to leverage our diverse patient population and bring in further efficiency in patient recruitment.”
“The population of India is significantly under-represented when it comes to participation in clinical research. Patient Network Explorer can cut a path through the forest, leading sponsors to the institutions and clinicians who can support clinical trials at an international level of expertise and facilities. This collaboration with Jehangir is just the first step in enabling a global population of eligible patients which reflects the diversity of the world, itself,” says Ian Rentsch, CEO of Clinerion.